Bausch, GBTC, Merck, Meta & Other Catalysts

A ruling by Oct. 1 in litigation challenging Medicare drug-negotiation provisions under the Inflation Reduction Act, an Oct. 3 Supreme Court argument on the CFPB’s constitutionality and the Department of Justice’s case against the JetBlue-Spirit M&A on Oct. 16 are key catalysts to watch next month. This Bloomberg Intelligence litigation and policy outlook episode of the Votes and Verdicts podcast, hosted by financials litigation analyst Elliott Stein, gathered the team to discuss these and other catalysts. Bayer faces a bellwether trial starting Oct. 5 concerning claims that Monsanto’s Roundup weedkiller causes cancer. In tech, Meta has an Oct. 17 hearing concerning its use of teens’ data. In health care, Bausch Health has an Oct. 6 hearing to stop Norwich’s bid for final FDA approval of its Xifaxan copy and a trial starts Oct. 23 in Exelixis’ bid to keep Cabometyx generics off the market. In financials, Virtu likely responds to the SEC’s Sept. 12 lawsuit, and we’re also watching the agency’s next moves on a spot bitcoin ETF. Other topics reviewed included marijuana-banking legislation, regional bank long-term debt requirements and the potential government shutdown.See omnystudio.com/listener for privacy information.